| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5702510 | Urologic Oncology: Seminars and Original Investigations | 2017 | 7 Pages |
Abstract
A decrease in CRP as well as pretreatment CRP can be a predictive factor for OS in patients with mRCC treated with a tyrosine kinase inhibitor. Cases with mRCC could be stratified into 3 groups with different prognoses using the pretreated CRP and its changes.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Jun M.D., Ph.D., Kohei M.D., Shunsuke M.D., Ph.D., Shogo M.D., Tetsutaro M.D., Ph.D., Shinya M.D., Ph.D., Koji M.D., Ph.D., Yasuhisa M.D., Ph.D., Satoshi M.D., Ph.D., Mitsuru M.D., Ph.D., Masanobu M.D., Ph.D., Hideki M.D., Ph.D., Hiroyuki M.D., Ph.D.,